Literature DB >> 9822356

Renal tolerability of teicoplanin in a case of neonatal overdose.

V Fanos1, M Mussap, B J Khoory, S Vecchini, M Plebani, D Benini.   

Abstract

The literature does not contain reports regarding teicoplanin overdose in newborns. In a neonate with a history of recent postasphyctic acute renal failure which recovered within 7 days of life, antibiotic therapy with teicoplanin was started for sepsis due to Staphylococcus hominis. However, for 5 days the dosage was excessive (20 mg/kg twice daily instead of an initial dose of 16 mg/kg and then doses of 8 mg/kg once daily). Once this error had been noted, therapy was immediately suspended. Clinically the newborn had improved and blood culture at the end of the therapy was negative. Biohumoral tests revealed constantly normal levels of serum creatinine, serum cystatin C and blood nitrogen. Urinary parameters of tubulotoxicity were also within normal values. Urinary epidermal growth factor was increased. Teicoplanin was well tolerated at the renal level in the newborn even in this case of excessive dosage.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9822356     DOI: 10.1179/joc.1998.10.5.381

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  5 in total

Review 1.  Clinical pharmacokinetics of teicoplanin.

Authors:  A P Wilson
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

Review 2.  Antibacterial-induced nephrotoxicity in the newborn.

Authors:  V Fanos; L Cataldi
Journal:  Drug Saf       Date:  1999-03       Impact factor: 5.606

Review 3.  Antibiotics in neonatal infections: a review.

Authors:  V Fanos; A Dall'Agnola
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

4.  Pharmacokinetics of teicoplanin in an ICU population of children and infants.

Authors:  John C Lukas; Georgios Karikas; Maria Gazouli; Panagiotis Kalabalikis; Tasos Hatzis; Panos Macheras
Journal:  Pharm Res       Date:  2004-11       Impact factor: 4.200

5.  Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages.

Authors:  Federico Pea; Pierluigi Viale; Anna Candoni; Federica Pavan; Leonardo Pagani; Daniela Damiani; Marco Casini; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.